Insulet Expands Diabetes Innovation with Automated Insulin Delivery System Launch in the Middle East
Published: 25 Mar 2026
Author: Precedence Research
Insulet Corporation has announced the introduction of its advanced automated insulin delivery system in the Middle East, marking a strategic expansion if its global footprint and reinforcing its commitment to advancing diabetes care through innovative technologies.
The new systems combine continuous glucose monitoring with insulin delivery controlled by algorithms to allow for real-time adjustment of the insulin delivery depending on the dynamic changes in glucose. This smart automation will go a long way in minimizing the necessary human factor and increasing the levels of glycaemic control with the reduction of hyperglycaemia threats. The design of the system focuses on ease of use, portability, and comfort of patients to enhance compliance with treatment regimes.
According to Precedence research, the artificial pancreas device system market was estimated at USD 410.20 million in 2025 and is predicted to increase from USD 480.75 million in 2026 to approximately USD 2,005.73 million by 2035, expanding at a CAGR of 17.20% from 2026 to 2035. The artificial pancreas device system market is a paradigm shift in the treatment of diabetes and combines the continuous glucose levels with automated insulin injection into the body to replicate the pancreatic functions. With the increasing rate of diabetes across the world, there is a demand for accurate, real-time glucose control devices, which encourages the use of such systems.
The Middle East is an emerging market for diabetes management solutions due to the increase in the prevalence of diseases and the demand for more advanced therapeutic technologies. Insulate will be able to bridge the critical shortcoming in diabetes care and offer patients more efficient and personalized treatment options by launching its automated insulin delivery platform in the region. Such highly developed systems should have a positive impact on enhancing clinical outcomes in a variety of patients.
More so, the introduction occurs in line with other health care trends that focus on digital transformation, remote monitoring, and home-based treatment. Medical practitioners throughout the area are moving towards technology-based solutions that are integrated and enable continuous monitoring of patients, and making decisions based on the data. The growth of Insulet is thus expected to speed up the implementation of automated insulin delivery systems and help modernize the healthcare facilities in the regions.
On the contrary, this innovation is a great step towards the further evolution of the technologies of the artificial pancreas. Insulet is aiding this trend in making the management of diabetes more accurate, efficient, and patient-focused by increasing its availability of innovative solutions in the Middle East market.